Abstract
Purpose
To assess if ratios of T1-weighted (T1w) signal intensity (SI) and quantitative T1 relaxometry (qT1) change on serial administration of macrocyclic gadobutrol.
Methods
A total of 17 glioblastoma patients were scanned at 3.0 T magnetic resonance imaging (MRI) every 6 weeks after tumor resection with standard MRI and T1 and T2 relaxometry before and after gadobutrol administration. On co-registered images T1w SI was measured and relaxation times T1 (qT1) and quantitative T2 (qT2) were quantified in several deep grey matter nuclei as ratios relative to frontal white matter and to the pons. Ratio changes were evaluated over time with a paired t‑test and multiple regression.
Results
An average of 8 (range 5–14) scans per patient were completed. Ratios of T1w SI, qT1 and qT2 remained unchanged for all target regions from the first to the last time point (p > 0.05) and did not correlate with the number of gadobutrol administrations. Multivariate regression showed no significant impact of gadobutrol on qT1 or qT2 ratios, but a significant negative effect on T1w SI ratios. Gender also had no impact on the ratios but age had a significant negative influence on the qT1 ratio.
Conclusion
Multiple administrations of a macrocyclic contrast agent did not change relaxation time T1 ratios in any deep grey matter structure.
Similar content being viewed by others
Abbreviations
- GBCA:
-
Gd-based contrast agent
- MRI:
-
Magnetic resonance imaging
- qT1:
-
T1 relaxation time
- qR1:
-
R1 relaxation rate
- qT2:
-
T2 relaxation time
- ROI:
-
Region of interest
- SI:
-
Signal intensity
- T1w:
-
T1-weighted
- TE:
-
Echo time
- TFE:
-
Ultrafast gradient echo
- TI:
-
Inversion time
- TR:
-
Repetition time
- TSE:
-
Turbo spin echo
References
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834–41.
Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol. 2016;37:1192–8.
Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5:82–8.
Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients. Scand J Urol Nephrol. 2007;41:565–6.
Roccatagliata L, Vuolo L, Bonzano L, Pichiecchio A, Mancardi GL. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology. 2009;251:503–10.
Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P, Heiland S, Wick W, Schlemmer H‑P, Bendszus M. Gadolinium retention in the dentate nucleus and Globus Pallidus is dependent on the class of contrast agent. Radiology. 2015;275:150337.
Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M. High-signal intensity in the dentate nucleus and Globus Pallidus on Unenhanced T1-weighted images: evaluation of the Macrocyclic gadolinium-based contrast agent Gadobutrol. Invest Radiol. 2015;50:805–10.
Radbruch A, Haase R, Kickingereder P, Bäumer P, Bickelhaupt S, Paech D, Wick W, Schlemmer HP, Seitz A, Bendszus M. Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a Macrocyclic gadolinium-based contrast agent. Radiology. 2017;283:828–36.
Radbruch A, Haase R, Kieslich PJ, Weberling LD, Kickingereder P, Wick W, Schlemmer HP, Bendszus M. No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of Macrocyclic gadolinium-based contrast agents. Radiology. 2017;282:699–707.
Chandra T, Mohan S. Role of contrast in MR imaging. Top Magn Reson Imaging. 2016;25:151–156.
Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol. 2003;13:2688–98.
Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293–352.
Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast age. Eur Radiol. 2016;26:807–15.
Tedeschi E, Palma G, Canna A, Cocozza S, Russo C, Borrelli P, Lanzillo R, Angelini V, Postiglione E, Morra VB, Salvatore M, Brunetti A, Quarantelli M. In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents. Eur Radiol. 2016;26:4577–84.
Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228–32.
Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and Bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol. 2016;51:447–53.
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772–82.
Nyúl LG, Udupa JK. On standardizing the MR image intensity scale. Magn Reson Med. 1999;42:1072–81.
Deoni SCL. Quantitative relaxometry of the brain. Top Magn Reson Imaging. 2010;21:101–13.
Weiskopf N, Suckling J, Williams G, Correia MMM, Inkster B, Tait R, Ooi C, Bullmore TET, Lutti A. Quantitative multi-parameter mapping of R1, PD*, MT, and R2* at 3T: A multi-center validation. Front Neurosci. 2013;7:1–11.
Müller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Mädler B, Schild HH, Glas M, Hattingen E. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma. Cancer Med. 2017;6(1):89–99. doi:10.1002/cam4.966.
Mädler B, Harris T, MacKay AL. 3D-relaxometry—quantitative T1 and T2 brain mapping at 3T. Proceedings of the 14th scientific meeting, International Society for Magnetic Resonance in Medicine, Seattle, USA, 2006, 14, p. 958.
Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011;46:292–300.
Jost G, Frenzel T, Lohrke J, Lenhard DC, Naganawa S, Pietsch H. Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol. 2016;27:2877–85.
Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol. 2017;52(7):396–404. doi:10.1097/RLI.0000000000000352.
Badve C, Yu A, Rogers M, Ma D, Liu Y, Schluchter M, Sunshine J, Griswold M, Gulani V. Simultaneous T1 and T2 brain relaxometry in asymptomatic volunteers using magnetic resonance fingerprinting. Tomography. 2015;1:136–44.
Gracien RM, Nürnberger L, Hok P, Hof SM, Reitz SC, Rüb U, Steinmetz H, Hilker-Roggendorf R, Klein JC, Deichmann R, Baudrexel S. Evaluation of brain ageing: a quantitative longitudinal MRI study over 7 years. Eur Radiol. 2016;27:1568–76.
Acknowledgements
We thank GL for help with statistics, our MRI technicians for excellent technical support and the patients and their families for their participation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
A. Müller, A. Jurcoane, P. Ditter, H. Schild and E Hattingen declare that they have no competing interests. B. Mädler is employee of Philips GmbH.
Additional information
Andreas Müller and Alina Jurcoane contributed equally to the manuscript.
Authors Contribution
Data were analyzed and controlled by authors who were not employed by or a consultant for a company in the medical industry and all authors have seen and approved the revised manuscript.
Rights and permissions
About this article
Cite this article
Müller, A., Jurcoane, A., Mädler, B. et al. Brain relaxometry after macrocyclic Gd-based contrast agent. Clin Neuroradiol 27, 459–468 (2017). https://doi.org/10.1007/s00062-017-0608-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00062-017-0608-6